Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a 'Buy' rating on Sarepta Therapeutics (NASDAQ:SRPT), but has lowered the price target from $185 to $82.
October 31, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics' price target has been lowered from $185 to $82 by Needham, though the 'Buy' rating is maintained.
The lowering of the price target by Needham indicates a potential decrease in the stock's value. However, the maintained 'Buy' rating suggests that the stock is still expected to perform well in the long term. This could lead to short term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100